Caricamento...
The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
BACKGROUND: Besifloxacin ophthalmic suspension 0.6 % (Besivance(®); Bausch & Lomb, Rochester, NY, USA) was approved by the FDA in 2009 for the treatment of bacterial conjunctivitis, with a recommended 7-day dosing regimen. OBJECTIVE: The objective of this study was to compare the safety of besif...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3851703/ https://ncbi.nlm.nih.gov/pubmed/24142473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40268-013-0029-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|